T cells targeted against a single minor histocompatibility antigen can cure solid tumors

Nature Medicine

Volumn 11, Issue 11, 2005, Pages 1222-1229

  Meunier, Marie Christine ^a,b   Delisle, Jean Sébastien ^a,b   Bergeron, Julie ^b   Rineau, Vincent ^a,b   Baron, Chantai ^a,b   Perreault, Claude ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP H ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MINOR HISTOCOMPATIBILITY ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CONTROLLED STUDY; CONVALESCENCE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; LYMPHOID ORGAN; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TUMOR CELL; TUMOR REJECTION; UPREGULATION; VITILIGO;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERFERON TYPE II; MICE; MICE, CONGENIC; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA;

EID: 30744448160     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1311     Document Type: Article

References (40)

1. Finn, O.J. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003).
2. Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
3. Bleakley, M. & Riddell, S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 4, 371-380 (2004).
4. Perreault, C. & Brochu, S. Adoptive cancer immunotherapy: discovering the best targets. J. Mol. Med. 80, 212-218 (2002).
5. Molldrem, J.J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 1018-1023 (2000).
6. Fontaine, P. et al. Adoptive transfer of T lymphocytes targeted to a single immunodominant minor histocompatibility antigen eradicates leukemia cells without causing graft-versus-host disease. Nat. Med. 7, 789-794 (2001).
7. Meunier, M.C., Roy-Proulx, G., Labrecque, N. & Perreault, C. Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy. Blood 101, 766-770 (2003).
8. + T-cell response. Nat. Rev. Immunol. 4, 595-602 (2004).
9. Pion, S. et al. On the mechanisms of immunodominance in cytotoxic T lymphocyte responses to minor histocompatibility antigens. Eur. J. Immunol. 27, 421-430 (1997).
10. Roy-Proulx, G., Meunier, M.C., Lanteigne, A.M., Brochu, S. & Perreault, C. Immunodomination results from functional differences between competing CTL. Eur. J. Immunol. 31, 2284-2292 (2001).
11. dom1) encoded by the classical H7 minor histocompatibility locus. J. Immunol. 162, 4502-4510 (1999).
12. Rubio, V. et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9, 1377-1382 (2003).
13. Harrington, L.E., Galvan, M., Baum, L.G., Altman, J.D. & Ahmed, R. Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J. Exp. Med. 191, 1241-1246 (2000).
14. von Andrian, U.H. & Mackay, C.R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343, 1020-1034 (2000).
15. Issekutz, A.C. & Issekutz, T.B. The role of E-selectin, P-selectin, and very late activation antigen-4 in T lymphocyte migration to dermal inflammation. J. Immunol. 168, 1934-1939 (2002).
16. Thatte, J., Dabak, V., Williams, M.B., Braciale, T.J. & Ley, K. LFA-1 is required for retention of effector CD8 T cells in mouse lungs. Blood 101, 4916-4922 (2003).
17. Dunn, G.P., Old, L.J. & Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
18. Spiotto, M.T., Rowley, D.A. & Schreiber, H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10, 294-298 (2004).
19. Griem, P. et al. Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 65, 633-640 (1991).
20. Schroder, K., Hertzog, P.J., Ravasi, T. & Hume, D.A. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163-189 (2004).
21. + effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J. Immunol. 170, 4427-4431 (2003).
22. Ogasawara, K. et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20, 757-767 (2004).
23. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54 (2004).
24. Butcher, E.C. & Picker, L.J. Lymphocyte homing and homeostasis. Science 272, 60-66 (1996).
25. Siegelman, M.H., Stanescu, D. & Estess, P. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J. Clin. Invest. 105, 683-691 (2000).
26. Nandi, A., Estess, P. & Siegelman, M. Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity 20, 455-465 (2004).
27. Kuzu, I., Bicknell, R., Fletcher, C.D. & Gatter, K.C. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab. Invest. 69, 322-328 (1993).
28. Dienst, A. et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J. Natl. Cancer Inst. 97, 733-747 (2005).
29. Byrne, G.J. et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J. Natl. Cancer Inst. 92, 1329-1336 (2000).
30. Amatschek, S. et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res. 64, 844-856 (2004).
31. Gervois, N., Guilloux, Y., Diez, E. & Jotereau, F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183, 2403-2407 (1996).
32. Hernandez, J., Lee, P.P., Davis, M.M. & Sherman, L.A. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol. 164, 596-602 (2000).
33. Yoshimura, Y. et al. Duration of alloantigen presentation and avidity of T cell antigen recognition correlate with immunodominance of CTL response to minor histocompatibility antigens. J. Immunol. 172, 6666-6674 (2004).
34. Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349-354 (2005).
35. Morgan, R.A. et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171, 3287-3295 (2003).
36. Korngold, R., Leighton, C., Mobraaten, L.E. & Berger, M.A. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens. Biol. Blood Marrow Transplant. 3, 57-64 (1997).
37. Klein, C.A. et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J. Exp. Med. 196, 359-368 (2002).
38. Spierings, E., Wieles, B. & Goulmy, E. Minor histocompatibility antigens - big in tumour therapy. Trends Immunol. 25, 56-60 (2004).
39. de Bueger, M., Bakker, A., Van Rood, J.J., van der Woude, F. & Goulmy, E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 149, 1788-1794 (1992).
40. Liu, L. et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 8, 185-189 (2002).